NDA 216387 · Astrazeneca
Calquence
Acalabrutinib Maleate · Oral · Kinase Inhibitor
Accelerated approvalOrphanLast checked: Nov 20, 2026Latest source record: Feb 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Aug 3, 2022
Approved uses
4
Original approval plus efficacy supplements
Registered trials
168
23 Phase 3, 38 recruiting
FAERS reports
12,744
10,675 serious, 2,699 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 19, 2026.
CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). (1.1 ) • For the treatment of adult patients with MCL who have received at least one prior therapy. ( 1.2 ) • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.3 ) 1.1 Previously Untreated Mantle Cell Lymphoma CALQUENCE in combination with bendamustine and rituximab is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). 1.2 Previously Treated Mantle Cell Lymphoma CALQUENCE is indicated for the treatment of adult patients with MCL who have received at least one prior therapy. 1.3 Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Mechanism: Acalabrutinib is a small-molecule inhibitor of Bruton tyrosine kinase (BTK). Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, acalabrutinib inhibited BTK‑mediated activation of downstream signaling proteins CD86 and CD69...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 19, 2026 Supplement 6 · Efficacy OrphanLetterLabel
- Jan 16, 2025 Supplement 5 · Efficacy · priority review OrphanLabelLetter
- Aug 3, 2022 Original approval · Type 3 - New Dosage Form Accelerated approvalOrphanLabelReview
- Aug 3, 2022 Original approval · Type 3 - New Dosage Form OrphanLetterLabelReview
1 products under this application
- CALQUENCE · ACALABRUTINIB MALEATE EQ 100MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Acalabrutinib" as an intervention, any sponsor and status, largest first.
- MACE and BTK InhibitorsNot yet recruiting
University Hospital, CaenAcademic, hospital or other
NCT07923162 · 10,000 participants (planned) · Start Dec 1, 2026 · Primary completion Feb 1, 2027
Drug: ibrutinib; Acalabrutinib and 1 more · For: Hematologic Cancer; MACE; BTK Inhibitors
Sites: Caen, France
- Public Health Emergency: SOLIDARITY TRIAL PhilippinesPivotal-lookingCompleted
University of the PhilippinesAcademic, hospital or other
NCT05024006 · 1,314 participants · Start Apr 23, 2020 · Primary completion Apr 17, 2021
Drug: Remdesivir; Hydroxychloroquine and 3 more · For: Covid19
Sites: Baguio City, Philippines; Cebu City, Philippines; Davao City, Philippines · 25 sites in all
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136559 · 1,200 participants (planned) · Start Dec 13, 2023 · Primary completion Sep 7, 2032
Drug: Nemtabrutinib; Ibrutinib and 1 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Mobile, Alabama; Gilbert, Arizona; Phoenix, Arizona · 206 sites in all
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPivotal-lookingActive, not recruiting
Acerta Pharma BVAstraZeneca (AZN)
NCT03836261 · 984 participants · Start Feb 25, 2019 · Primary completion Apr 30, 2027
Drug: Acalabrutinib; Venetoclax and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Los Angeles, California; Redondo Beach, California; Fort Wayne, Indiana · 169 sites in all
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT03740529 · 803 participants · Start Mar 15, 2019 · Primary completion Jan 27, 2025
Drug: Pirtobrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma and 3 more
Sites: Scottsdale, Arizona; San Diego, California; San Francisco, California · 56 sites in all
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLPivotal-lookingActive, not recruiting
Acerta Pharma BVAstraZeneca (AZN)
NCT02972840 · 635 participants · Start Apr 5, 2017 · Primary completion Feb 15, 2027
Drug: Acalabrutinib; Bendamustine and 2 more · For: Lymphoma, Mantle Cell
Sites: Tucson, Arizona; Downey, California; Santa Monica, California · 228 sites in all
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Pivotal-lookingActive, not recruiting
Acerta Pharma BVAstraZeneca (AZN)
NCT04529772 · 611 participants · Start Oct 8, 2020 · Primary completion Feb 22, 2027
Drug: acalabrutinib; placebo and 5 more · For: Diffuse Large B-Cell Lymphoma
Sites: Tucson, Arizona; Little Rock, Arkansas; Irvine, California · 245 sites in all
- A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05057494 · 607 participants · Start Sep 12, 2022 · Primary completion Jul 15, 2027
Drug: Acalabrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sites: Tucson, Arizona; La Jolla, California; Longmont, Colorado · 37 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death2,186
- fatigue725
- headache657
- product dose omission issue522
- diarrhoea443
- fall395
- dyspnoea352
- contusion351
- pneumonia337
- malignant neoplasm progression325
- asthenia314
- pain302
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 44 |
| 2018 | 193 |
| 2019 | 198 |
| 2020 | 588 |
| 2021 | 1,080 |
| 2022 | 1,443 |
| 2023 | 2,240 |
| 2024 | 2,719 |
| 2025 | 2,330 |
| 2026 | 1,908 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Calquence (Acalabrutinib)
2024 spending
$564K
Beneficiaries
18
41 claims
Per beneficiary
$31,341
$231.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $349,971,873 |
| 2021 | $774,700,145 |
| 2022 | $1,028,537,752 |
| 2023 | $59,763,180 |
| 2024 | $564,130 |
Part D: Calquence (Acalabrutinib Maleate)
2024 spending
$1.70B
Beneficiaries
15,056
122,356 claims
Per beneficiary
$113,043
$248.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $164,376,683 |
| 2023 | $1,286,819,830 |
| 2024 | $1,701,974,921 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
Brown JR, Seymour JF, Jurczak W, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Wang M, Salek D, Belada D, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Multicenter Study
- Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
Sharman JP, Egyed M, Jurczak W, et al. · Blood 2025 · Clinical Trial, Phase III, Multicenter Study
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Byrd JC, Hillmen P, Ghia P, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Comparative Study
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP, Egyed M, Jurczak W, et al. · Lancet 2020 · Clinical Trial, Phase III, Multicenter Study
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M, Rule S, Zinzani PL, et al. · Lancet 2018 · Clinical Trial, Phase II, Multicenter Study
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.